CMPX - Compass Therapeutics, Inc.
IEX Last Trade
1.46
0.005 0.342%
Share volume: 6,769
Last Updated: Fri 27 Dec 2024 08:30:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.46
0.00
0.34%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
0.66%
1 Month
-2.56%
3 Months
-19.15%
6 Months
26.67%
1 Year
1.33%
2 Year
-71.43%
Key data
Stock price
$1.46
DAY RANGE
$1.46 - $1.56
52 WEEK RANGE
$0.86 - $2.34
52 WEEK CHANGE
-$2.56
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Thomas J. Schuetz
Region: US
Website: compasstherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: compasstherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trials for colorectal and ovarian cancer.
Recent news